Cas:1239662-47-5 [(5R)-3-{3-Fluoro-4-[6-(2H-tetrazol-5-yl)-3-pyridinyl]phenyl}-2-oxo-1,3-oxazolidin-5-yl]methyl dihydrogen phosphate manufacturer & supplier

Chemical Name:[(5R)-3-{3-Fluoro-4-[6-(2H-tetrazol-5-yl)-3-pyridinyl]phenyl}-2-oxo-1,3-oxazolidin-5-yl]methyl dihydrogen phosphate

CAS.NO:1239662-47-5

Synonyms:[(5R)-3-{3-Fluoro-4-[6-(2H-tetrazol-5-yl)-3-pyridinyl]phenyl}-2-oxo-1,3-oxazolidin-5-yl]methyl dihydrogen phosphate;2-Oxazolidinone, 3-[3-fluoro-4-[6-(2H-tetrazol-5-yl)-3-pyridinyl]phenyl]-5-[(phosphonooxy)methyl]-, (5R)-

Molecular Formula:C₁₆H₁₄FN₆O₆P

Molecular Weight:436.291

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:743.2±70.0 °C at 760 mmHg

Density:1.7±0.1 g/cm3

Index of Refraction:1.647

PSA:

Exact Mass:436.069641

LogP:0.94

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like [(5R)-3-{3-Fluoro-4-[6-(2H-tetrazol-5-yl)-3-pyridinyl]phenyl}-2-oxo-1,3-oxazolidin-5-yl]methyl dihydrogen phosphate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Oxazolidinone, 3-[3-fluoro-4-[6-(2H-tetrazol-5-yl)-3-pyridinyl]phenyl]-5-[(phosphonooxy)methyl]-, (5R)- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Oxazolidinone, 3-[3-fluoro-4-[6-(2H-tetrazol-5-yl)-3-pyridinyl]phenyl]-5-[(phosphonooxy)methyl]-, (5R)- Use and application,2-Oxazolidinone, 3-[3-fluoro-4-[6-(2H-tetrazol-5-yl)-3-pyridinyl]phenyl]-5-[(phosphonooxy)methyl]-, (5R)- technical grade,usp/ep/jp grade.

Related News: As for argenx’s efgartigimod, that drug hasn’t scored an FDA nod yet and its eventual cost-effectiveness will depend on its price. benzyl (5S,8S,11S)-5-(hydroxymethyl)-3,6,9-trioxo-1-phenyl-8,11-dipropyl-2-oxa-4,7,10-triazadodecan-12-oate manufacturers Given ICER’s uncertainty regarding efgartigimod’s dosing and long-term benefits, the group said it’s moderately certain the drug can produce a “comparable, small or substantial net health benefit” in that same group of MG patients. O-mesitoylacetoxime suppliers In SLE, along with the pivotal TULIP phase III programme, anifrolumab continues to be evaluated in a long-term extension phase III trial.12 A phase II trial of anifrolumab in SLE using subcutaneous delivery has been completed. 5-methoxy-8-(4-methoxy-phenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-f]chromen-10-one vendor & factory.